

University of Groningen

## Paving ways for personalizing drug therapy during pregnancy

Daud, Nur

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2017

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Daud, N. (2017). *Paving ways for personalizing drug therapy during pregnancy: A focus on the risk of drug teratogenicity*. Rijksuniversiteit Groningen.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

**Paving ways for personalizing drug therapy during pregnancy:  
A focus on the risk of drug teratogenicity**

1. The most important knowledge on the safety of a drug used during pregnancy is not to prove that the drug is hazardous, but to identify who can benefit from it, and who cannot.
2. Placental transporter proteins need more attention, as their role in drug distribution can be very important in determining fetal exposure to drugs taken by the mother during pregnancy.
3. Data on pharmacogenetic predictors should be incorporated in systems biology-based models to better estimate the pharmacokinetics or distribution of drugs taken during pregnancy.
4. Pharmacogenetics may create hope in preventing drug teratogenicity. In the future, pharmacogenetic screening should be recommended to pregnant women to whom potentially teratogenic drugs are prescribed, while alternative drug therapy options should be readily available.
5. Congenital anomalies might inflict a significant medical and psychological burden on the affected individuals and their families. The search for the risk factors or mechanisms behind it might be intriguing for us as researchers, but not necessarily for them.
6. Education is the key to increase awareness and acceptance of the concept of pharmacogenetics as well as the advantages that it can offer towards personalized drug therapy.
7. Personalized medicine is underway, but it is also evolving. Efforts are needed to gather the growing evidence and develop guidelines to accomplish the optimal drug therapy management that we wish for.
8. Doing research is like making one piece of a puzzle. We can imagine the whole picture, but it will not be clear until we have finished the entire puzzle. Contributing only one piece of a puzzle is already a challenge.
9. Life is full of uncertainties. Just grasp the feeling of the moment, and cherish ourselves with what we have.
10. After you have wept and grieved for your physical losses, cherish the functions and the life you have left. (Morrie Schwartz)